| Pair Name | Naringenin, ABT-737 | ||
| Phytochemical Name | Naringenin (PubChem CID: 439246 ) | ||
| Anticancer drug Name | ABT-737 (PubChem CID: 11228183 ) | ||
| Structure of Phytochemical |
|
Download
2D
MOL
3D
MOL
|
|
| Structure of Anticancer Drug |
|
Download
2D
MOL
3D
MOL
|
|
| Pair Name | Naringenin, ABT-737 | |||
| Disease Info | [ICD-11: 2B72] | Gastric cancer | Investigative | |
| Gene Regulation | Down-regulation | Phosphorylation | AKT1 | hsa207 |
| Up-regulation | Cleavage | CASP3 | hsa836 | |
| Up-regulation | Cleavage | PARP1 | hsa142 | |
| In Vitro Model | SGC-7901 | Human papillomavirus-related cervical adenocarcinoma | Homo sapiens (Human) | CVCL_0520 |
| Result | The combination of these drugs was found to further increase the cleavage of caspase-3 and poly ADP-ribose polymerase. Naringenin and ABT-737 also decreased Akt activation and increased p53 expression, suggesting the involvement of these pathways in the inhibition of gastric cell growth. | |||
| No. | Title | Href |
|---|---|---|
| 1 | Enhanced anticancer effect of ABT-737 in combination with naringenin on gastric cancer cells. Exp Ther Med. 2016 Feb;11(2):669-673. doi: 10.3892/etm.2015.2912. | Click |
